Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease
Lund, Sweden May 30, 2023. Hansa Biopharma (“Hansa”), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Søren Tulstrup, President and CEO, Hansa Biopharma said, “This is an exciting next step in the development of imlifidase and for patients with anti-GBM disease. GOOD-IDES-02 is the first and currently only pivotal randomized trial in anti-GBM disease, a condition with significant unmet medical